title: A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma.
abstract: Potential synergistic interaction between gemcitabine (GEM) and epirubicin (EPI) in pancreatic cancer have been described previously. The maximum-tolerated dose in this trial was GEM 1000 mg m(-2) and EPI 45 mg m(-2). Median time to progression was 5.1 months and median survival time 7.4 months. This combination appears well tolerated and shows promising clinical activity.
authors.affiliation: Medical Department C, Klinikum Ludwigshafen gGmbH, Bremserstr.79, Ludwigshafen D-67063, Germany. eickhofa@klilu.de
authors.forename: A
authors.initials: A
authors.lastname: Eickhoff
authors.forename: W
authors.initials: W
authors.lastname: Martin
authors.forename: D
authors.initials: D
authors.lastname: Hartmann
authors.forename: J C
authors.initials: JC
authors.lastname: Eickhoff
authors.forename: M
authors.initials: M
authors.lastname: Möhler
authors.forename: P R
authors.initials: PR
authors.lastname: Galle
authors.forename: J F
authors.initials: JF
authors.lastname: Riemann
authors.forename: R
authors.initials: R
authors.lastname: Jakobs
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D015251:Epirubicin / Q000627:therapeutic use* / Q000633:toxicity*; D005260:Female; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D010976:Platelet Count; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D006454:Hemoglobins; D003841:Deoxycytidine; D015251:Epirubicin; D000093542:Gemcitabine